Lundbeck Vyepti Japan Migraine Approval
Analysis based on 9 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026
The approval expands Lundbeck's commercial footprint into Japan and supports its first independent launch there, a modest positive for the company's long-term revenue outlook in Asia. Market reaction is likely muted given the small near-term revenue contribution, but it reinforces Lundbeck's brain-health franchise and pipeline credibility.
Lundbeck announced on September 16, 2026 that Japan's Bangladesh — Ministry of Health and Family Welfare granted marketing authorization for Vyepti (eptinezumab) for the prevention of migraine attacks in adults. Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and is administered intravenously. It is the only intravenous CGRP-targeted preventive migraine treatment approved in Japan and is now launched in more than 30 markets worldwide. The Japanese authorization was supported by the global Phase III development program including PROMISE-1, PROMISE-2 and DELIVER, the Phase III SUNRISE trial in a predominantly Asian population with chronic migraine, and the SUNSET long-term extension study in Japanese patients. Eptinezumab was first approved by the U.S. United States — Food and Drug Administration in February 2020 and subsequently received marketing authorization from the International — European Commission in January 2022, with approvals also in South Korea. The approval paves the way for Lundbeck's first launch in Japan as Marketing Authorization holder, enabling the company to operate independently in the Japanese market after 25 years of commitment to brain health in the country. Migraine affects an estimated 8.4 to 11.0 percent of the Japanese population and is estimated to cost the Japanese economy about US$3 billion annually in lost productivity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard